Skip to main content
. 2007 Nov 8;44(9):729–733. doi: 10.1080/02770900701595667

Figure 1.

Figure 1

(A) Maximum percent decrease in FEV1 for each patient from postdose/pre-challenge after treatment with placebo (DB-placebo) or levalbuterol (DB-levalbuterol) during the double-blind period for each patient. Patient numbers (see Table 2) are indicated and the solid grey lines are to aid following individual patient values. LS-mean (Least square mean) is the adjusted means for the effects in the model (see methods). (B) Percent of patients protected at 10%, 15%, and 20% is indicated.